Defining a role and predicting benefit from platinum-based therapy in breast cancer: an evolving story

Affiliations

Editorial

Joseph A Sparano. J Clin Oncol. 2015.

. 2015 Jan 1;33(1):1-3.

doi: 10.1200/JCO.2014.57.7890. Epub 2014 Oct 20.

¹ Montefiore-Einstein Center for Cancer Care, Albert Einstein Cancer Center, Bronx, NY jsparano@montefiore.org.

No abstract available

Comment on

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Sikov WM, et al. J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. J Clin Oncol. 2015. PMID: 25092775 Free PMC article. Clinical Trial.